Cargando…

Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies

PURPOSE: Magnetic resonance imaging (MRI) contrast agents are pharmaceuticals that enable a better visualization of internal body structures. In this study, we present the synthesis, MRI signal enhancement capabilities, in vitro as well as in vivo cytotoxicity results of gold-coated iron oxide nanop...

Descripción completa

Detalles Bibliográficos
Autores principales: Iancu, Stefania D, Albu, Camelia, Chiriac, Liviu, Moldovan, Remus, Stefancu, Andrei, Moisoiu, Vlad, Coman, Vasile, Szabo, Laszlo, Leopold, Nicolae, Bálint, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355080/
https://www.ncbi.nlm.nih.gov/pubmed/32753867
http://dx.doi.org/10.2147/IJN.S253184
_version_ 1783558207932727296
author Iancu, Stefania D
Albu, Camelia
Chiriac, Liviu
Moldovan, Remus
Stefancu, Andrei
Moisoiu, Vlad
Coman, Vasile
Szabo, Laszlo
Leopold, Nicolae
Bálint, Zoltán
author_facet Iancu, Stefania D
Albu, Camelia
Chiriac, Liviu
Moldovan, Remus
Stefancu, Andrei
Moisoiu, Vlad
Coman, Vasile
Szabo, Laszlo
Leopold, Nicolae
Bálint, Zoltán
author_sort Iancu, Stefania D
collection PubMed
description PURPOSE: Magnetic resonance imaging (MRI) contrast agents are pharmaceuticals that enable a better visualization of internal body structures. In this study, we present the synthesis, MRI signal enhancement capabilities, in vitro as well as in vivo cytotoxicity results of gold-coated iron oxide nanoparticles (Fe(3)O(4)@AuNPs) as potential contrast agents. METHODS: Fe(3)O(4)@AuNPs were obtained by synthesizing iron oxide nanoparticles and gradually coating them with gold. The obtained Fe(3)O(4)@AuNPs were characterized by spectroscopies, transmission electron microscopy (TEM) and energy dispersive X-ray diffraction. The effect of the nanoparticles on the MRI signal was tested using a 7T Bruker PharmaScan system. Cytotoxicity tests were made in vitro on Fe(3)O(4)@AuNP-treated retinal pigment epithelium cells by WST-1 tests and in vivo by following histopathological changes in rats after injection of Fe(3)O(4)@AuNPs. RESULTS: Stable Fe(3)O(4)@AuNPs were successfully prepared following a simple and fast protocol (<1h worktime) and identified using TEM. The cytotoxicity tests on cells have shown biocompatibility of Fe(3)O(4)@AuNPs at small concentrations of Fe (<1.95×10(−8) mg/cell). Whereas, at higher Fe concentrations (eg 7.5×10(−8) mg/cell), cell viability decreased to 80.88±5.03%, showing a mild cytotoxic effect. MRI tests on rats showed an optimal Fe(3)O(4)@AuNPs concentration of 6mg/100g body weight to obtain high-quality images. The histopathological studies revealed significant transient inflammatory responses in the time range from 2 hours to 14 days after injection and focal cellular alterations in several organs, with the lung being the most affected organ. These results were confirmed by hyperspectral microscopic imaging of the same, but unstained tissues. In most organs, the inflammatory responses and sublethal cellular damage appeared to be transitory, except for the kidneys, where the glomerular damage indicated progression towards glomerular sclerosis. CONCLUSION: The obtained stable, gold covered, iron oxide nanoparticles with reduced cytotoxicity, gave a negative T(2) signal in the MRI, which makes them suitable for candidates as contrast agent in small animal MRI applications.
format Online
Article
Text
id pubmed-7355080
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73550802020-08-03 Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies Iancu, Stefania D Albu, Camelia Chiriac, Liviu Moldovan, Remus Stefancu, Andrei Moisoiu, Vlad Coman, Vasile Szabo, Laszlo Leopold, Nicolae Bálint, Zoltán Int J Nanomedicine Original Research PURPOSE: Magnetic resonance imaging (MRI) contrast agents are pharmaceuticals that enable a better visualization of internal body structures. In this study, we present the synthesis, MRI signal enhancement capabilities, in vitro as well as in vivo cytotoxicity results of gold-coated iron oxide nanoparticles (Fe(3)O(4)@AuNPs) as potential contrast agents. METHODS: Fe(3)O(4)@AuNPs were obtained by synthesizing iron oxide nanoparticles and gradually coating them with gold. The obtained Fe(3)O(4)@AuNPs were characterized by spectroscopies, transmission electron microscopy (TEM) and energy dispersive X-ray diffraction. The effect of the nanoparticles on the MRI signal was tested using a 7T Bruker PharmaScan system. Cytotoxicity tests were made in vitro on Fe(3)O(4)@AuNP-treated retinal pigment epithelium cells by WST-1 tests and in vivo by following histopathological changes in rats after injection of Fe(3)O(4)@AuNPs. RESULTS: Stable Fe(3)O(4)@AuNPs were successfully prepared following a simple and fast protocol (<1h worktime) and identified using TEM. The cytotoxicity tests on cells have shown biocompatibility of Fe(3)O(4)@AuNPs at small concentrations of Fe (<1.95×10(−8) mg/cell). Whereas, at higher Fe concentrations (eg 7.5×10(−8) mg/cell), cell viability decreased to 80.88±5.03%, showing a mild cytotoxic effect. MRI tests on rats showed an optimal Fe(3)O(4)@AuNPs concentration of 6mg/100g body weight to obtain high-quality images. The histopathological studies revealed significant transient inflammatory responses in the time range from 2 hours to 14 days after injection and focal cellular alterations in several organs, with the lung being the most affected organ. These results were confirmed by hyperspectral microscopic imaging of the same, but unstained tissues. In most organs, the inflammatory responses and sublethal cellular damage appeared to be transitory, except for the kidneys, where the glomerular damage indicated progression towards glomerular sclerosis. CONCLUSION: The obtained stable, gold covered, iron oxide nanoparticles with reduced cytotoxicity, gave a negative T(2) signal in the MRI, which makes them suitable for candidates as contrast agent in small animal MRI applications. Dove 2020-07-07 /pmc/articles/PMC7355080/ /pubmed/32753867 http://dx.doi.org/10.2147/IJN.S253184 Text en © 2020 Iancu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Iancu, Stefania D
Albu, Camelia
Chiriac, Liviu
Moldovan, Remus
Stefancu, Andrei
Moisoiu, Vlad
Coman, Vasile
Szabo, Laszlo
Leopold, Nicolae
Bálint, Zoltán
Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
title Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
title_full Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
title_fullStr Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
title_full_unstemmed Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
title_short Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
title_sort assessment of gold-coated iron oxide nanoparticles as negative t2 contrast agent in small animal mri studies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355080/
https://www.ncbi.nlm.nih.gov/pubmed/32753867
http://dx.doi.org/10.2147/IJN.S253184
work_keys_str_mv AT iancustefaniad assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT albucamelia assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT chiriacliviu assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT moldovanremus assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT stefancuandrei assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT moisoiuvlad assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT comanvasile assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT szabolaszlo assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT leopoldnicolae assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies
AT balintzoltan assessmentofgoldcoatedironoxidenanoparticlesasnegativet2contrastagentinsmallanimalmristudies